Wegovy pill keeps early lead over Foundayo in oral obesity market

Novo Nordisk's oral Wegovy held roughly a four-to-one lead over Eli Lilly's Foundayo in weekly prescriptions in the most recent reporting period, according to IQVIA data cited by Citi and published in Fierce Pharma's oral GLP-1 tracker. The Wegovy pill recorded about 183,000 total prescriptions for the week, up from 181,000 the week before, while Foundayo rose nearly 8% to 47,500 ^[2].

Both totals were the highest each drug had reached ^[2].

The gap has narrowed slowly rather than closed. In the week covered by an Aug. 28 update, Foundayo passed 40,000 weekly prescriptions for the first time, at 40,862, 20 weeks into its launch. At week six of its own launch, the Wegovy pill had drawn roughly 57,000 prescriptions ^[2]. By its 33rd week, the Wegovy pill was booking about 175,000 ^[2], and it now accounts for around 35% of all Wegovy prescriptions, including the injectable version ^[2].

One caveat applies to the Foundayo numbers: Citi analysts said IQVIA may still be missing some Foundayo prescriptions filled through telehealth channels, so the reported figures may understate its actual volume ^[2].

Analysts tie the early lead to two factors: timing and coverage. The Wegovy pill launched in January 2026, about three months before Foundayo ^[2]. Jefferies noted that CVS was the last of the three major pharmacy benefit managers to cover Foundayo, starting June 1, 2026, while the Wegovy pill had full coverage in its first week on the market ^[2]. Lilly said it began broad direct-to-consumer marketing after securing commercial access across the three major PBMs in June ^[2].

The business results have been uneven. Lilly reported $98 million in second-quarter Foundayo sales, including $67 million in the U.S., a figure that disappointed many analysts ^[2]. Jefferies modeled about $71 million in U.S. sales for the quarter ^[2].

At the class level, Citi said total GLP-1 prescriptions rose 5.4% over the last four weeks, compared with a 6.8% decline in the same period a year earlier, and attributed the 12-percentage-point swing to oral GLP-1s drawing in new patients ^[2]. Lilly's tirzepatide holds nearly 57% of the total GLP-1 market, up from about 49.5% a year earlier, while Novo's semaglutide has stayed roughly flat at 37% ^[2].

Why it matters for patients

There are now two oral GLP-1 options for weight management in the U.S., and which one a patient can get at a predictable cost depends heavily on insurance. The Wegovy pill had full commercial coverage from its launch week, while Foundayo waited about four months for the last of the three major PBMs to add it ^[2].

Pricing and coverage also differ by product. The list price for injectable Wegovy is about $1,349.02 per month and for Ozempic about $968.52 per month, with eligible patients often paying less through insurance or manufacturer programs ^[1]. A list price for Foundayo has not been reported in the launch coverage.

The Medicare GLP-1 Bridge program, which went live July 1, 2026, offers coverage for certain weight-loss medications, including Foundayo, for a $50 copayment per month ^[2].

Oral Wegovy was approved by the FDA in December 2025 ^[1]. Both companies are still reporting weekly prescription data, and early launch trends do not establish how the market will settle.

What happens next

The tracker is updated weekly with IQVIA figures cited by Citi and Jefferies, so the prescription gap will keep being measured as Foundayo's formulary position improves ^[2]. Whether Novo Nordisk can hold its lead as coverage expands has not been answered ^[2]. Formulary decisions for the next plan year have not been disclosed.

New clinical data and any further label changes for either pill have not been announced in the launch coverage. Foundayo sales for the current quarter have not yet been reported.